Developing life-saving therapies for blood cancer patients

Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative and potentially life‑saving therapies for patients with late stage blood cancers and related disorders in need of a transplant, an area of significant unmet medical need.

The Company is currently sponsoring a multi‑center Phase II clinical trial for its lead product ATIR™ and is collaborating with renowned centers in Europe and North America.








Click to download the Company Fact Sheet which provides a valuable insight into where Kiadis Pharma stands today. It summarizes what the Company's lead product ATIR™ is about, its market potential and the progress that is being made in clinical development.



News Digest



Kiadis Pharma has recently been granted a U.S. patent regarding the Company’s lead product ATIR™, a cell-based treatment in development that enables partially matched stem cells from family members to be used in reconstituting the immune system of blood cancer patients.

Kiadis Pharma was previously granted broad patent protection in the U.S. for the full ATIR™ manufacturing process, the device and the therapeutic use of ATIR™, and the patent recently granted (United States Patent No. 8,802,082) has now extended this protection to an additional rhodamine derivative.

 



ATIR™ Phase I/II study completed



5‑year follow‑up of patients with high‑risk malignancies from Phase I/II clinical study confirms long‑term safety and efficacy of ATIR™ over a broad dose range.


 

Upcoming Conferences



Advanced Therapies Investor Day
November 13, 2014 - London, United Kingdom

American Society of Hematology (ASH) Annual Meeting
December 6-9, 2014 - San Francisco, USA

Phacilitate Cell & Gene Therapy Forum
January 26-28, 2015 - Washington DC, USA